Are Pattern Recognition Receptors Associated with Hepatocellular Carcinoma?

Turk J Gastroenterol

Division of Gastroenterology, Department of Internal Medicine, Necmettin Erbakan University, Meram School of Medicine, Meram, Konya, Turkey.

Published: July 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Hepatocellular carcinoma (HCC) is one of the important causes of mortality due to malignancy. Toll-like receptors (TLRs) are very important in liver pathophysiology in terms of their roles in the innate immune system, such as the regulation of inflammation, wound healing, stimulation of adaptive immune responses, promotion of epithelial regeneration, and carcinogenesis. In this study, we planned to examine the role of TLR1 (rs4833095, rs5743551) and nucleotide-binding oligomerization domain (NOD2) (rs2066844, rs2066845, rs2066847) polymorphisms in the development of HCC and their effects on the clinical presentation of HCC patients.

Methods: Our study was designed prospectively. Cirrhotic and HCC patients who were followed up in our clinic between January 2015 and September 2018 were included in the study. Sex, age, cirrhosis etiology, Child-Pugh class, and MELD scores were recorded. TLR1 and NOD2 polymorphisms were studied by the PCR method.

Results: HCC developed in 88 (31.4%) of the 280 patients who were followed up, either during the recruitment phase of our study or during the follow-up. The mean follow-up time of our patient group was 17.04 ± 11.72 months, and the mean follow-up time of HCC patients was 12.09 ± 10.26 months. TLR1 (rs5743551) polymorphism was associated with HCC development (P = .003). TLR1 (rs5743551) and NOD2 (rs2066844) polymorphisms were associated with the development of spontaneous bacterial peritonitis (SBP) in the HCC patient group (P = .013 and P = .021, respectively).

Conclusion: We think that increased bacterial translocation in cirrhotic patients may contribute to HCC development by causing chronic inflammation, especially in patients with TLR 1 (rs5743551) polymorphism.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975513PMC
http://dx.doi.org/10.5152/tjg.2021.20657DOI Listing

Publication Analysis

Top Keywords

hcc
9
nod2 rs2066844
8
hcc patients
8
follow-up time
8
patient group
8
tlr1 rs5743551
8
rs5743551 polymorphism
8
hcc development
8
patients
5
pattern recognition
4

Similar Publications

Response to the Letter to the Editor Regarding "Assessing the link between post-treatment ALT and HCC risk in chronic hepatitis C".

J Formos Med Assoc

September 2025

Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Center of Hepatitis Research, College of Medicine and Center of Metabolic Disorders and Obesity, Kaohsiung Medical University, Kaohsiung, Taiwan. Electroni

View Article and Find Full Text PDF

Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.

View Article and Find Full Text PDF

Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.

View Article and Find Full Text PDF

Background: Advanced-stage hepatocellular carcinoma (HCC) with high tumour burden and portal vein tumour thrombus (PVTT) is usually associated with poor survival outcomes. Rapid tumour control usually benefits long-term outcomes, which could be hardly achieved by solely systematic targeted and immunotherapy in current guidelines. Hepatic arterial infusion chemotherapy (HAIC) is reported as an effective intervention for rapid decrease of tumour burden.

View Article and Find Full Text PDF

Supplementary Material for Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data from Nine Countries.

Clin Gastroenterol Hepatol

September 2025

The Global NASH/MASH Council, Washington, DC, United States; Gastroenterology Section, Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Liver, Digestive, and Lifestyle Health Research Section, and Organ Transplant Center of Excellence, King Faisal Sp

Background And Aim: Although the clinical burden of MASH is well known, its economic burden is less well described. We estimated MASH's economic burden in several regions of the world including the US, Germany, Spain, France, Italy, and United Kingdom (UK), Japan, Saudi Arabia, and Brazil over the next two decades.

Methods: A one-year cycle Markov model projected MASH progression from 2021 to 2040, incorporating 2020 prevalent cases and annual incident cases (2021-2040).

View Article and Find Full Text PDF